ORLANDO, Fla.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous ...

Despite the benefits and accessibility of administering cancer medications and fluids subcutaneously vs. intravenously, U.S. facilities appear to underuse this delivery method, according to a research ...

Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma Authors retain all rights in ...

The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.

Nodule and lipoma formation can occur rarely after an intramuscular influenza vaccination, particularly when administered ...

Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for ...

- Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with ...

Subcutaneous (SC) administration of medication and fluids for end-of-life cancer care is underutilized in the United States, despite this route having advantages over intravenous (IV) administration, ...

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...

May 19, 2010 — A voluntary recall has been issued for all lots of Baxter's hyaluronidase human injection (Hylenex) because of the presence of particulate matter, identified as glass, according to a ...